CanAg® Glypican-3 EIA

The CanAg^® Glypican-3 EIA Assay is a solid phase, 2-step immunoassay for determination of human Glypican-3 (GPC3) in serum.

Liver cancer is a global health issue, and its incidence is progressively increasing worldwide. It has been estimated that every year more than 800,000 people are diagnosed with liver cancer globally, and that by 2025 this disease will affect more than 1 million individuals. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer in adults, accounting for about 80% of cases (other forms include cholangiocarcinoma in 10–20% of cases). In the majority of cases, HCC is a direct consequence of chronic liver inflammation and cirrhosis, and major risk factors include persistent Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection, heavy alcohol consumption, ingestion of aflatoxin B1, smoking, and nonalcoholic fatty liver disease (NAFLD). This assay is for Research Use Only (RUO) and may not be used for diagnostic purposes.

Why test for serum Glypican-3?

• Surveillance testing for individuals at high risk may enable early detection of HCC                    CanAg^® Glypican-3 EIA Product Sheet
• Glypican-3 is a promising therapeutic target for HCC                                                                              This email address is being protected from spambots. You need JavaScript enabled to view it.
• Serum Glypican-3 may be an indicator of HCC progression                                                                                   Order now